SubHero Banner

Sivextro® (tedizolid) – Expanded indication

June 19, 2020 - The FDA approved Merck’s Sivextro (tedizolid), in adult and pediatric patients 12 years of age and older, for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillin-resistant [MRSA] and methicillin-susceptible [MSSA] isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus Group (including Streptococcus anginosus, Streptococcus intermedius, and Streptococcus constellatus), and Enterococcus faecalis.

Download PDF